Mirtazapine Does Not Reduce Agitation in Dementia Patients
In randomized, double-blind trial, no difference seen in scores for agitated behaviors at 12 weeks with mirtazapine versus placebo
Dementia
Risk for Dementia Not Increased With Menopausal Hormone Therapy
Risk for dementia decreased for cases and controls younger than 80 years who had been taking estrogen-only therapy for 10 years or more
Dietary Flavonoids May Lower Odds of Subjective Cognitive Decline
Associations strongest for flavones, flavanones, anthocyanins; dose-response curve steepest for flavones, then anthocyanins
Relapse Risk for Psychosis in Dementia Lower With Continued Pimavanserin
Findings seen in double-blind, randomized, placebo-controlled discontinuation trial that was stopped early for efficacy
AAN Presents Ethical Considerations Relating to Dementia Care
Timely anticipatory planning in early dementia is crucial to preserve autonomy over future decisions and to reduce caregiver strain
Statin Use Not Tied to Cognitive Decline, Dementia in Seniors
No association seen for statin use vs nonuse with dementia, MCI, or changes in cognitive function over time
Tdap Vaccination Tied to Lower Dementia Risk in Older Adults
Findings seen in two cohorts of older adults with different sociodemographic characteristics
FDA Rejects Pimavanserin sNDA for Dementia-Related Psychosis
The sNDA submission was supported by data from the pivotal phase 3 HARMONY study.
Additional Administration Option Approved for Nuplazid Capsules
Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson disease psychosis.
Anticholinergics Linked to Increased Dementia Risk
Physicians should carefully weigh the risks against the potential benefits before prescribing anticholinergics, according to investigators.
